ArcticZymes Technologies ASALTS:0DRV 77 Altman Z-Score is 19.34 as of Jul. 02, 2026, which is 31% below its 10-year median of 27.91. GuruFocus rates LTS:0DRV with a GF Score™ of 77/100 and a GF Value™ of kr23.85 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 929 Biotechnology companies, ArcticZymes Technologies ASA ranks better than 87.73% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 19.08 is strong.
ArcticZymes Technologies ASA has a Altman Z-Score of 19.34, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for ArcticZymes Technologies ASA's Altman Z-Score or its related term are showing as below:
LTS:0DRV'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.55 Med: 27.91 Max: 100.44
Current: 19.08
During the past 13 years, ArcticZymes Technologies ASA's highest Altman Z-Score was 100.44. The lowest was 1.55. And the median was 27.91.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRV vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
ArcticZymes Technologies ASA (LTS:0DRV) has a Altman Z-Score of 19.34 as of Jul. 02, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on ArcticZymes Technologies ASA and its competitors. This is 31% below median its historical median of 27.91. Over the past decade, ArcticZymes Technologies ASA's Altman Z-Score has ranged from 1.55 to 100.44. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #114 out of 929 companies in the Biotechnology industry, placing it in the top 12.3%.
Is ArcticZymes Technologies ASA's Altman Z-Score too high?
ArcticZymes Technologies ASA's current Altman Z-Score of 19.34 is 31% below median its 10-year median of 27.91. Over the past 10 years, this metric has ranged from a low of 1.55 to a high of 100.44. The Biotechnology industry median Altman Z-Score is 2.61. ArcticZymes Technologies ASA's value of 19.34 is 641% above this industry median. Based on the distribution chart, ArcticZymes Technologies ASA ranks #114 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #114 out of 929 companies for Altman Z-Score. This places ArcticZymes Technologies ASA in the top 12% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.61. ArcticZymes Technologies ASA's value of 19.34 is 641% above this benchmark. Historically, ArcticZymes Technologies ASA's own Altman Z-Score has ranged from 1.55 to 100.44 over the past decade. While the company's 10-year median is 27.91 vs. the industry median of 2.61, ArcticZymes Technologies ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.61, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ArcticZymes Technologies ASA's current Altman Z-Score of 19.34 is 641% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on ArcticZymes Technologies ASA and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArcticZymes Technologies ASA's current Altman Z-Score is 19.34, which is 31% below median its own 10-year median of 27.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr23.85, compared to a current price of kr20.90 — trading 12.4% below its estimated fair value. The current Altman Z-Score is 19.34, which is 31% below median its 10-year median of 27.91 and 641% above the Biotechnology industry median of 2.61. ArcticZymes Technologies ASA's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current Altman Z-Score is 19.34 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr20.90 is trading 12.4% below its estimated GF Value™ of kr23.85.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
Altman Z-Score: 19.34 (31% below median its 10-year median of 27.91)
GF Value™: kr23.85 vs. price of kr20.90 (12.4% below fair value)
Industry Position: 641% above the Biotechnology median (#114 of 929)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
77GF Score
Get the complete analysis for LTS:0DRV
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
